ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Clinical trials for ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill combo aims to delay chemo in advanced breast cancer
Disease control Not yet recruitingThis phase 3 trial is testing two oral drugs, camizestrant and ribociclib, as a first treatment for people with ER-positive, HER2-negative advanced breast cancer. The goal is to see if the combination can delay the need for next cancer therapy. About 150 participants will take th…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Zapping resistant tumors: could radiation extend the life of current breast cancer therapy?
Disease control Not yet recruitingThis trial is for people with ER-positive, HER2-negative advanced breast cancer whose disease has started to grow in a few spots while on hormone therapy and a CDK4/6 inhibitor. It tests whether adding targeted radiation (SABR) to those spots allows patients to stay on their curr…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: NA • Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC